Otsuka looks to maximise growth before Abilify watershed
This article was originally published in Scrip
Executive Summary
Otsuka Holdings has unveiled its first mid-term business plan since going public in a $2.4 billion IPO in Japan late last year, under which it is looking to raise net sales of pharmaceuticals (including nutrition solutions) to ¥847.0 billion ($10.47 billion) in the fiscal year to 31 March 2014, up from ¥721.4 billion last fiscal year.